India’s Healthcare Patent Playbook: Generic IP, Biosimilar Roadmaps, and the $50B MedTech Bet
How Section 3(d), compulsory licensing, and frugal innovation combine to make India the world’s most structurally disruptive pharmaceutical market, and […]
Price vs. Product in Pharma: The IP, Patent, and Value-Based Pricing Playbook Decision-Makers Actually Need
The debate framed as ‘price versus product’ in pharmaceutical competition has always been a false binary. Every drug launch, every
Expired Pharma Patents: The $356 Billion Intelligence Asset Most Companies Ignore
How abandoned and expired patents in pharmaceutical manufacturing reveal synthesis routes, competitor strategy, and biosimilar opportunities your R&D team is
Expired Pharma Patents: The $356 Billion Intelligence Asset Most Companies Ignore Read Post »
What are the top Biopharmaceutical Business Intelligence Services?
Executive Summary: The Transition from Data Aggregation to Prescriptive Analytics The global biopharmaceutical industry operates within an environment of unprecedented
What are the top Biopharmaceutical Business Intelligence Services? Read Post »
A Comprehensive Generic Drug Naming Resource: Decoding the Pharmaceutical Alphabet
Pharmaceutical nomenclature is the foundation of market transparency and intellectual property enforcement. While brand names drive consumer preference, the generic
A Comprehensive Generic Drug Naming Resource: Decoding the Pharmaceutical Alphabet Read Post »
Biosimilar Patent Litigation: The Complete Prediction Framework for IP Teams and Portfolio Managers
I. What the Global Biosimilar Market Actually Looks Like Right Now The biosimilar market reached approximately USD 40.4 billion in
Can Drug Companies Bribe the FDA? Unveiling the Truth Behind Pharmaceutical Influence
FDA Regulatory Integrity and the Mechanics of Pharmaceutical Market Entry The relationship between pharmaceutical manufacturers and the Food and Drug
Can Drug Companies Bribe the FDA? Unveiling the Truth Behind Pharmaceutical Influence Read Post »
Predicting Drug Patent Litigation Outcomes
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need to read case trajectories — not just
Predicting Drug Patent Litigation Outcomes Read Post »
Drug Patent Lifecycle: The Complete Pharma IP Strategy Playbook
I. Executive Summary Pharmaceutical patents are not legal formalities. They are the single most important determinant of whether a drug
Drug Patent Lifecycle: The Complete Pharma IP Strategy Playbook Read Post »
